Bial

Share Interview Share Compensation

N/A

Clinical Trials (1)

NCT03959540Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

N/A

Help build intelligence for Bial

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active clinical pipeline with 20 ongoing trials across Phase 1-3, particularly in high-need areas like Parkinson's disease and epilepsy
Diversified therapeutic focus spanning infectious diseases, vaccines, and CNS disorders provides exposure to multiple disease areas
European-based biotech with potential upside from eslicarbazepine acetate programs in Phase 3 (partial epilepsy in adults and pediatric populations)

Watch Out For

Zero active job openings currently listed indicates potential hiring freeze or limited growth phase
Pipeline heavily concentrated in Phase 1 programs (7 of 12 unique drug programs) with unclear commercial viability and high attrition risk
Missing financial data (revenue, R&D spend, cash position, funding history) prevents assessment of company stability and career runway

Generated by Claude from Bial's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ESL

N/A

Clinical Trials (1)

NCT01532726Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

N/A

Opicapone 50 mg

N/A

Clinical Trials (1)

NCT07403799REal-life ON PARKinson's - ITaly (REONPARK-IT)

N/A

Hypnosis group intervention

Cancer

N/A

Clinical Trials (1)

NCT04873661Cognitive Trance, Hypnosis and Meditation in Oncology

N/A

SL-APO

N/A

Clinical Trials (1)

NCT07145190SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

N/A

Injex

Allergic Rhinitis

N/A

Clinical Trials (1)

NCT02965612Specific Immunotherapy for Allergic Child

N/A

BIA 28-6156

N/A

Clinical Trials (1)

NCT07522606Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study

N/A

Gratitude letter

Positive Emotions

N/A

Clinical Trials (1)

NCT05133063The Impact of a Gratitude Intervention on Stress Reactivity

N/A

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02170376The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Phase 1

rasagiline

PHASE_1

Clinical Trials (1)

NCT01532128Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Phase 1

BIA 2-093

PHASE_1

Clinical Trials (1)

NCT02170649The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02169466Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02169453Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02169895Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Phase 1

BIA 2-093

PHASE_1

Clinical Trials (1)

NCT02287415The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02071810Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Phase 1

BIA 2-093

PHASE_1

Clinical Trials (1)

NCT01678976Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Phase 1

Placebo

PHASE_1

Clinical Trials (1)

NCT03097211Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT01520727A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

Phase 1

BIA 3-202

PHASE_1

Clinical Trials (1)

NCT02778594Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Phase 1

Metformin

Neuropathic Pain

PHASE_1

Clinical Trials (1)

NCT00971295Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers

Phase 1

BIA 2-093

PHASE_1

Clinical Trials (1)

NCT02283814A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02169440Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Phase 1

BIA 3-202

Healthy

PHASE_1

Clinical Trials (1)

NCT02779348Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02169479Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT01533077Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Phase 1

BIA 6-512 400 mg

PHASE_1

Clinical Trials (1)

NCT03095092Effect of Food on BIA 6-512 (Trans-resveratrol)

Phase 1

BIA 2-093

PHASE_1

Clinical Trials (1)

NCT02281526An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Phase 1

BIA 2-093

Pulmonary Arterial Hypertension

PHASE_1

Clinical Trials (1)

NCT02777671Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Phase 1

BIA 5-1058

PHASE_1

Clinical Trials (1)

NCT04675944Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Phase 1

BIA 9-1067 5 mg

Pulmonary Arterial Hypertension

PHASE_1

Clinical Trials (1)

NCT02169414Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Phase 1

BIA 5-1058

PHASE_1

Clinical Trials (1)

NCT04994860Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Phase 1

Placebo

Hypertension

PHASE_1

Clinical Trials (1)

NCT03099226Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Phase 1

BIA 5-1058

Pulmonary Arterial Hypertension

PHASE_1

Clinical Trials (1)

NCT04991194Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058

Phase 1

eslicarbazepine acetate and Microginon®

Partial Epilepsy

PHASE_1

Clinical Trials (1)

NCT00898560Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Phase 1

50 mg BIA 9 1067

PHASE_1

Clinical Trials (1)

NCT04265027Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Phase 1

BIA 9-1067

Parkinson

PHASE_1

Clinical Trials (1)

NCT02071823Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Phase 1

BIA 2-093

PHASE_1

Clinical Trials (1)

NCT02284854Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Phase 1

200 mg BIA 6-512

PHASE_1

Clinical Trials (1)

NCT03095105Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Phase 1

BIA 2-093

PHASE_1

Clinical Trials (1)

NCT02284828Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Phase 1

BIA 9-1067

PHASE_1

Clinical Trials (1)

NCT02305329Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Phase 1

BIA 2-093

Hypertension and Chronic Heart Failure

PHASE_1

Clinical Trials (1)

NCT02172742The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Phase 1

BIA 5-1058

PHASE_1

Clinical Trials (1)

NCT02151994Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.

Phase 1

OPC

PHASE_1

Clinical Trials (1)

NCT02169427An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Phase 1

BIA 6-512